Investment Thesis
Standard Biotools exhibits a critical disconnect between balance sheet strength and operational deterioration. Despite $265.8M in cash and negligible debt, the company generated negative operating cash flow (-$46.6M) and negative free cash flow (-$47.2M), indicating unsustainable cash burn. The abnormally high net income (600.9% margin) appears driven by one-time items, masking operational losses and declining revenue that signal fundamental business challenges.
Strengths
- Fortress balance sheet with $561.1M equity and minimal debt exposure
- Exceptional liquidity position with 12.36x current ratio and $265.8M cash reserves providing downside protection
- Healthy gross margin of 53.5% demonstrates product-level profitability before operating overhead
Risks
- Severe negative operating cash flow (-$46.6M) and free cash flow (-$47.2M) indicate unsustainable cash consumption
- Operating losses (-$12.5M) with -59.1% operating margin show core business is not profitable
- Revenue decline of 6.2% YoY signals weakening market demand or competitive position
- Net income appears artificially inflated by one-time gains, masking operational deterioration; cash burn threatens viability within 5-6 years at current rate
Key Metrics to Watch
- Operating cash flow trend and path to positive OCF
- Revenue stabilization and return to growth
- Operating margin improvement and timeline to operating profitability
Financial Metrics
Revenue
21.1M
Net Income
127.1M
EPS (Diluted)
$0.33
Free Cash Flow
-47.2M
Total Assets
639.1M
Cash
265.8M
Profitability Ratios
Gross Margin
53.5%
Operating Margin
-59.1%
Net Margin
600.9%
ROE
22.6%
ROA
19.9%
FCF Margin
-223.1%
Balance Sheet & Liquidity
Current Ratio
12.36x
Quick Ratio
11.92x
Debt/Equity
0.00x
Debt/Assets
12.2%
Interest Coverage
-2.74x
Long-term Debt
299.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T09:32:41.250232 |
Data as of: 2026-03-31 |
Powered by Claude AI